Xuantai Pharmaceuticals (688247.SH) released its 2024 semi-annual report, with a revenue of 0.218 billion yuan...
According to the report for the first half of 2024 released by Xuantai Pharmaceuticals (688247.SH), the company's revenue was 0.218 billion yuan, an increase of 96.81% compared to the same period last year; the net income attributable to shareholders of the listed company was 54.1533 million yuan, an increase of 137.60% year-on-year; the net income attributable to shareholders of the listed company excluding non-recurring items was 48.7934 million yuan, an increase of 167.97% year-on-year; the basic earnings per share was 0.12 yuan/share. It plans to distribute a cash dividend of 0.25 yuan (tax included) per 10 shares to all shareholders.
